TP53 and neoplasm: Additionally, to rule out the tumorigenic risk of CEFFE treatment, the expression of tumor marker P53 (oncogenic gene) and PTEN (suppressive gene) was analyzed, and the results displayed no difference between each group, indicating that CEFFE had no tumorigenic risk for ovarian function recovery (Figures 3D, E).